Research · Sep 3, 2026
[IDYA] IDEAYA Biosciences Thesis 2026: Synthetic-Lethality Precision-Oncology Compounder
IDEAYA Biosciences (NASDAQ: IDYA), headquartered in South San Francisco, California, is a Synthetic-Lethality-Precision-Oncology + emerging-multi-cycle-IDE161-IDE397-Phase-3-and-Phase-2 leader providing distinctive multi-cycle IDE397-MAT2A-Inhibitor + emerging-IDE161-PARP-and-Pol-Theta-Inhibitor + emerging-Darovasertib-MGV-001-Uveal-Melanoma + emerging-IDE275-Werner-Helicase-WRN-Inhibitor services to substantial multi-cycle Pre-Commercial-Biotech-Clinical-Development-Patient-and-Physician-and-Health-Plan-target + multi-cycle-emerging-IDE397-MTAP-Deletion-Lung-and-Esophageal-and-Pancreatic-Patient-Population ~10,000-15,000 US-Patient + multi-cycle-emerging-IDE161-Pol-Theta-Patient-Population ~5,000-10,000 US-Patient + multi-cycle-emerging-Darovasertib-Uveal-Melanoma-Patient-Population ~2,000-3,000 US-Patient. The company has distinctive multi-cycle IDEAYA-Biosciences-and-South-San-Francisco-CA-and-Synthetic-Lethality-Precision-Oncology heritage: founded 2015 as IDEAYA-Biosciences-Yujiro-Hata-Founder-and-Daniel-Simon-Co-Founder; 2019 NASDAQ IDEAYA-Biosciences-IPO ($101M proceeds); 2020 substantial GSK-GlaxoSmithKline-Collaboration-Synthetic-Lethality-Phase-2-and-Phase-3; 2024 substantial Pfizer-Darovasertib-MGV-001-Uveal-Melanoma-Acquired ($210M providing emerging-multi-cycle-Darovasertib-Phase-3-Uveal-Melanoma); 2024 substantial Follow-On-Financing-and-Cash-Runway-Extension; 2024 substantial IDE397-Phase-2-and-IDE161-Phase-2-Clinical-Trial-Readouts; multi-cycle-disciplined-Synthetic-Lethality-Clinical-Stage-Pipeline-Advancement. FY2025 closes with selected various aggregate revenue ~$0M (pre-Commercial-Biotech-Phase-3-and-Phase-2-clinical-development), adjusted EBITDA ~$-225 to -165M (Pre-Commercial-Biotech-Clinical-Development-Burn), adjusted EPS ~$-2.85 to -2.05, net cash ~$1.10-1.30B (multi-cycle-Pre-Commercial-Biotech-Cash-Runway-into-2028), and ~80-85M shares outstanding under President & CEO Yujiro Hata. The IDE397-MAT2A-and-IDE161-PARP-and-Darovasertib-Uveal-Melanoma-and-Pipeline franchise deep-dive covers distinctive multi-cycle ~110-130 employees + ~South-San-Francisco-CA-HQ-Clinical-Development-Biotech-Office across US + emerging multi-jurisdiction-international (Multi-Clinical-Trial-Site-Europe-and-Asia-Pacific), Clinical-Stage-Biotech-Pipeline ~0% pre-Commercial-Biotech-revenue (IDE397-MAT2A-MTAP-Deletion-Phase-2 + IDE161-PARP-and-Pol-Theta-Phase-2 + Darovasertib-MGV-001-Uveal-Melanoma-Phase-3 + IDE275-Werner-Helicase-WRN-Phase-1 + Pipeline) + Emerging-GSK-Collaboration-Revenue ~0-1%, 2019-NASDAQ-IPO + 2020-GSK-Synthetic-Lethality-Collaboration + 2024-Pfizer-Darovasertib-MGV-001-acquired + 2024-Follow-On-Financing transformational-platform, emerging-multi-cycle Synthetic-Lethality-Precision-Oncology + emerging-MAT2A-MTAP-Deletion-Cancer + emerging-PARP-and-Pol-Theta-Cancer + emerging-Uveal-Melanoma + emerging-Werner-Helicase-WRN-MSI-Cancer + emerging-Biotech-M&A-Activity structural-tailwinds, competing in Synthetic-Lethality-Precision-Oncology space with AstraZeneca, Repare Therapeutics, Tango Therapeutics, Cyteir, BeiGene, Schrödinger, Kura Oncology, Mirati/BMY, Amgen, Pfizer (Darovasertib-divestor), Merck, BMS, Roche, Eli Lilly, Novartis, Sanofi, AbbVie, GSK (collaboration-partner), Vertex, Regeneron, Biogen; and private-equity-Flagship-ARCH-Third-Rock-Atlas-Polaris-Versant-OrbiMed-RA-Capital-Baker-Bros-Perceptive-Foresite-Avoro-TPG-Wildcat-Alger-Casdin. The Yujiro-Hata + Founder-CEO + multi-decade compounder thesis + 2020-GSK-and-2024-Pfizer-Darovasertib deep-dive covers Yujiro-Hata-Founder-CEO (~25+ year longtime-IDEAYA-Founder-and-Co-Founder-Daniel-Simon + Former-Forma-Therapeutics-CFO + Former-Onyx-Pharmaceuticals-veteran) expertise, 2015-IDEAYA-Biosciences-founding + 2019-NASDAQ-IPO + 2020-GSK-Synthetic-Lethality-Collaboration + 2024-Pfizer-Darovasertib-MGV-001-acquired + 2024-Follow-On-Financing-and-Cash-Runway-Extension transformational-platform, no-dividend (Pre-Commercial-Biotech-Clinical-Development-Burn). Capital position is Pre-Commercial-Biotech (Not-Rated-Pre-Commercial-Biotech + Pre-Commercial-Biotech-Cash-Runway-into-2028). At ~$22-32 per share, equity value ~$1.80-2.70B, providing Pre-Commercial-Biotech-Phase-3-and-Phase-2-Clinical-Trial-Readout-Option-Value.